Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for knee osteoarthritis pain
NCT04044742Phase 3Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
A Phase 3 trial of resiniferatoxin in osteoarthritis (OA), sponsored by Sorrento Therapeutics. Planned start Dec 2020; status: withdrawn.
02
Drugs
resiniferatoxin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04044742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044742.